Treatment of Bowen’s disease with photodynamic therapy. Observational study in 171 patients with 5-aminolaevulinic acid (BF-200 ALA) and methyl aminolaevulinate (MAL)

Alique-García, Sergio; Alique, Daniel; Company-Quiroga, Jaime; Sánchez, Alberto; Núñez, Almudena Hernández; Borbujo, J.

doi:10.1016/j.pdpdt.2019.08.011

Cited by 13 publications

(8 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Forty-three studies, enrolling a total of 1943 BD lesions and 282 SCC lesions between 1994 and 2019, were used for quantitative analysis. Thirty-two studies 1,2,5,6,11,15–41 used red light, whereas 9 studies 4,42–49 used laser. Twenty-four studies 3,4,6,16,21,28,31–38,40–42,44–50 used aminolevulinic acid (ALA), and 18 studies 1,2,5,11,15–19,22–27,29,30,39 used methyl aminolevulinate (MAL) as a photosensitizer (see Supplemental Digital Content 2 , Table S2, http://links.lww.com/DSS/B13).…”

Section: Resultsmentioning

confidence: 99%

“…Twenty studies 3,5,11,15,17,18,21, 31,32,34–37,42–44,46,47,49,50 reported predominantly small BD lesions, whereas 9 studies 4,20,23,25–27,34,45,48 reported predominantly large BD lesions. Eighteen studies reported BD primarily located on the extremities, 2,5,6,18,19,21,25,29,31–37,42,44,47 and 7 studies 3,11,15–17,43,45 reported the head/neck as the majority anatomic site. For cSCC, all lesions from 8 studies 3,4,11,39–41,45,48 reporting the lesion size were small lesions, and 7 of 8 studies reported the head/neck as the majority anatomic site.…”

Section: Resultsmentioning

confidence: 99%

“…Thirty-two studies 1,2,5,6,11, used red light, whereas 9 studies 4,42-49 used laser. Twenty-four studies 3,4,6,16,21,28,[31][32][33][34][35][36][37][38][40][41][42][44][45][46][47][48][49][50] used aminolevulinic acid (ALA), and 18 studies 1,2,5,11,[15][16][17][18][19][22][23][24][25][26][27]29,30,39 used methyl aminolevulinate (MAL) as a photosensitizer (see Supplemental Digital Content 2, Table S2, http://links.lww.com/DSS/ B13). Excluding studies that reported occlusion time as range (n 5 9) and mean occlusion time of 3.53 (SD 5 1.99) and 6.11 (SD 5 5.79) hours were found for BD and SCC, respectively.…”

Section: Study Selectionmentioning

confidence: 99%

“…Twenty studies 3,5,11,15,17,18,21,31,32,[34][35][36][37][42][43][44]46,47,49,50 reported predominantly small BD lesions, whereas 9 studies 4,20,23,[25][26][27]34,45,48 reported predominantly large BD lesions. Eighteen studies reported BD primarily located on the extremities, 2,5,6,18,19,21,25,29,[31][32][33][34][35][36][37]42,44,47 and 7 studies 3,11,[15][16]…”

Section: Study Selectionmentioning

confidence: 99%

See 3 more Smart Citations

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Yongpisarn

Rigo

Minkis

2022

View full text Add to dashboard Cite

BACKGROUND Although surgery is the treatment of choice for Bowen disease (BD) and cutaneous squamous cell carcinoma (cSCC), nonsurgical treatments such as photodynamic therapy (PDT) may be preferred for select tumors. Previous meta-analysis have failed to gather strong evidence to recommend PDT. OBJECTIVE This study evaluates the effectiveness of PDT in the treatment of cSCC and BD for clearance rate (CR) after 1 year. METHODS A literature search of studies of biopsy-proven BD and cSCC treated with PDT was performed. Pooled CRs were estimated. Subgroup analyses were performed based on follow-up, treatment regimen, lesion size, and site. RESULTS Forty-three studies were included, enrolling 1943 BD lesions and 282 SCC lesions. Pooled CRs for BD and SCC were 76% (95% CI: 71%–80%; I2 = 78.9%) and 51% (95% CI: 35%–66%; I2 = 85.7%), respectively. CONCLUSION Our findings support the selective use of PDT for BD; however, patients should be advised of potential for recurrence. Although PDT can be used for certain cases of cSCC, the high rate of treatment failure necessitates close surveillance for residual or recurrent disease. Further studies are needed to justify the usage of PDT in the treatment of BD and cSCC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Selectionmentioning

confidence: 99%

See 2 more Smart Citations

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Yongpisarn

Rigo

Minkis

2022

View full text Add to dashboard Cite

show abstract

“…PDT is presented as an alternative treatment for BCC tumors. PDT is regarded as highly appropriate treatment option for low‐risk tumors, such as Bowen's disease, 4 or sBCC 5 . The mainly advantages of PDT, when compared with topical treatments such as imiquimod or 5‐FU, include excellent compliance, short treatment duration (adherence), and better cosmetic results after treatment.…”

Section: Discussionmentioning

confidence: 99%

Treatment of superficial basal cell carcinoma with 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel ( BF ‐200 ALA ) and photodynamic therapy: Results in clinical practice in a tertiary hospital

Navarro‐Triviño

Ayén‐Rodríguez

Llamas‐Molina

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an effective treatment option for the treatment of superficial basal cell carcinoma (sBCC). Recent publications have demonstrated that PDT with 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel (BF‐200 ALA‐PDT) is an effective and safe alternative for the treatment of sBCC). To investigate the efficacy and safety of 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel (BF‐200 ALA)‐PDT for the treatment of sBCC. A non‐controlled, open‐label single centre study was conducted. Patients received one PDT cycle with two PDT sessions one‐week apart. In case that clinical‐dermoscopy evaluation of treatment outcome revealed remaining lesions, a second PDT cycle was performed. The clinical results at the dermoscopy and fluorescence diagnosis level were histologically confirmed in all patients. Treatment response was evaluated 3, 6, and 12 months after last PDT session. A total of 31 patients (12 men and 19 women), with a median age of 63.74 years were included in this study. 3‐month after PDT‐session, 23/31 patients were complete responders (74.19%) after two BF‐200 ALA ‐PDT sessions. Esthetic outcome was considered good‐to‐excellent. 5 Aminolevulinic acid 7.8% nanoemulsion‐based gel (BF‐200 ALA) PDT is an effective therapy option for the treatment of sBCC. Complete clearance rates were higher in those patients who received only one PDT cycle. These results show a similar tendency as shown in other publications.

show abstract

Role of Photodynamic Therapy in Oncodermatology

Bartolomeo

Pomi

Borgia

2023

Interdisciplinary Cancer Research

View full text Add to dashboard Cite

Treatment of Bowen’s disease with photodynamic therapy. Observational study in 171 patients with 5-aminolaevulinic acid (BF-200 ALA) and methyl aminolaevulinate (MAL)

Cited by 13 publications

References 4 publications

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Treatment of superficial basal cell carcinoma with 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel ( BF ‐200 ALA ) and photodynamic therapy: Results in clinical practice in a tertiary hospital

Role of Photodynamic Therapy in Oncodermatology

Contact Info

Product

Resources

About